World Health Organization, Geneva, Switzerland.
Department of Community Medicine, Aminu Kano Teaching Hospital & Bayero University, Kano, Nigeria.
Clin Infect Dis. 2018 Oct 30;67(suppl_1):S103-S109. doi: 10.1093/cid/ciy637.
Kano state has been a protracted reservoir of poliovirus in Nigeria. Immunity trends have been monitored through seroprevalence surveys since 2011. The survey in 2015 was, in addition, intended to assess the impact of use of inactivated poliovirus vaccine (IPV).
It was a health facility based seroprevalence survey. Eligible children aged 6-9, 12-15 and 19-22 months of age brought to the paediatrics outpatient department of Murtala Mohammad Specialist Hospital between 19 October and 6 November 2015, were screened for eligibility. Eligible children were enrolled after parental consent, history taken, physical examination conducted, and a blood sample collected to test for neutralizing antibody titres against the three poliovirus serotypes.
Overall, 365 results were available in the three age groups. In the 6-9-month-old age group, the seroprevalence was 73% (95% confidence interval [CI] 64-80%), 83% (95% CI 75-88%), and 66% (95% CI 57-73%) for serotypes 1, 2, and 3, respectively. In the 12-15- and 19-22-month-old age groups, seroprevalence was higher but still remained <90% across serotypes. Seroprevalence to serotypes 1 and 3 in 2015 was similar to 2014; however, for serotype 2 there was a significant improvement. IPV received in supplemental immunization activities was found to be a significant predictor of seropositivity among 6-9-month-old infants for serotypes 1 and 2.
Seroprevalence for serotypes 1 and 3 remains low (<80%) in 6-9-month-olds. This poses a significant risk for poliovirus spread if reintroduced into the population. Efforts to strengthen immunization coverage are imperative to secure and sustain high population immunity.
卡诺州一直是尼日利亚脊髓灰质炎病毒的长期蓄水池。自 2011 年以来,通过血清流行率调查监测免疫趋势。2015 年的调查还旨在评估使用灭活脊髓灰质炎病毒疫苗(IPV)的影响。
这是一项基于卫生机构的血清流行率调查。2015 年 10 月 19 日至 11 月 6 日期间,在穆尔塔拉·穆罕默德专科医院儿科门诊,筛选出年龄在 6-9 个月、12-15 个月和 19-22 个月的合格儿童。在获得父母同意、病史、体格检查和采集血液样本以检测针对三种脊髓灰质炎病毒血清型的中和抗体滴度后,合格的儿童将被纳入研究。
在这三个年龄组中,共有 365 个结果。在 6-9 个月大的年龄组中,血清型 1、2 和 3 的血清阳性率分别为 73%(95%置信区间 [CI] 64-80%)、83%(95% CI 75-88%)和 66%(95% CI 57-73%)。在 12-15 个月和 19-22 个月大的年龄组中,血清阳性率更高,但仍低于 90%。2015 年血清型 1 和 3 的血清阳性率与 2014 年相似;然而,血清型 2 的血清阳性率有显著改善。在 6-9 个月大的婴儿中,在补充免疫活动中接种 IPV 被发现是血清型 1 和 2 血清阳性的显著预测因素。
6-9 个月大的婴儿中血清型 1 和 3 的血清阳性率仍然较低(<80%)。如果重新引入人群,这将对脊髓灰质炎病毒的传播构成重大风险。加强免疫覆盖的努力对于确保和维持高人群免疫力至关重要。